TPST (tempesttx.com) קצב צמיחת רווח למניה בשנה הנוכחית

The annual EPS percentage difference demonstrates profit dynamics, where the current metric is 54.50. The absence of recurring revenue is driven by Tempest Therapeutics (TPST) focusing on clinical trials for targeted therapy. Developments in treating liver cancer via immune response confirm the growth stage. Meanwhile, competent management effectively attracts venture capital, ensuring high transparency in pipeline reporting.

For the biotechnology startup Tempest Therapeutics (TPST), which develops targeted oncology therapies, this indicator serves as a measure of the efficiency of innovation capitalization. The metric calculates the percentage deviation of current earnings per share from the same value last year. Analyzing the YoY net income per share trend allows for tracking the company's pace of financial transformation. Growth in this figure confirms the success of drug commercialization, while negative trends signal high R&D expenditures.